



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/Cancer Care Nova Scotia**

**Guidelines for the Role of Aprepitant as Antiemetic Therapy with Highly
Emetogenic Cancer Chemotherapy (HEC)**

Approved Use:

Aprepitant: In combination with a 5-HT₃ antagonist and dexamethasone in adult cancer patients treated with chemotherapy that includes **cisplatin** as a **single day therapy greater than or equal to 70mg/m²** to prevent acute and delayed nausea and vomiting. Aprepitant may be considered as an option at the onset of cisplatin-based therapy ($\geq 70\text{mg/m}^2$) and commence with the first cycle of this HEC. In any one patient, the following criteria include:

1. Aprepitant will only be used with single day cisplatin-based therapy $\geq 70\text{mg/m}^2$ (and not multiple day cisplatin chemotherapy).
 2. Aprepitant will not be used in patients receiving moderately emetogenic cancer chemotherapy or radiotherapy.
 3. The 5-HT₃ antagonist should only be used on the first day of cisplatin therapy with aprepitant continuing on Day 2 and Day 3.
 4. The dose of dexamethasone may be adjusted due to the increased levels of dexamethasone when combined with aprepitant.
- This policy recommendation represents a **new guideline document** and a restriction of aprepitant to include patients treated with cisplatin $\geq 70\text{mg/m}^2$ and commence with the first cycle of this HEC.